Fecal Microbiota Transplant in 2026: What's Approved, What's Investigational, and What's Hype

Fecal microbiota transplant, or FMT, is exactly what it sounds like: transferring stool from a healthy donor into the gastrointestinal tract of a patient to restore microbial diversity and function. It is also one of the most genuinely effective treatments in all of microbiome medicine, at least for one specific condition. For recurrent Clostridioides difficile infection, FMT resolves symptoms in roughly 80 to 90% of cases where antibiotics have failed repeatedly (van Nood et al., 2013). That success rate is remarkable by any standard. But the story of FMT in 2026 is about much more than C. diff. It is about the collision of a powerful therapy with a complex regulatory landscape, the closure of the nonprofit stool bank that made FMT accessible for a decade, the development of next-generation products that might replace donor stool entirely, and a growing underground of DIY practitioners who are skipping all of this and doing it themselves. Here is where things actually stand.

What is FDA-approved right now

As of early 2026, two microbiota-based products have received FDA approval, both specifically for the prevention of recurrence of Clostridioides difficile infection in adults who have completed antibiotic treatment for recurrent C. diff.

Rebyota (fecal microbiota, live-jslm), manufactured by Ferring Pharmaceuticals, was approved in November 2022. It is a rectally administered product derived from screened donor stool. The PUNCH CD3 trial showed that Rebyota reduced C. diff recurrence to 29.4% compared to 42.5% with placebo at 8 weeks, a statistically significant difference (Khanna et al., 2022). It is administered as a single rectal dose, which is a practical advantage but does require a clinical setting.

Vowst (fecal microbiota spores, live-brpk), developed by Seres Therapeutics, was approved in April 2023 as the first orally administered microbiota product. It contains purified Firmicutes spores derived from donor stool. The ECOSPOR III trial demonstrated a recurrence rate of 12.4% with Vowst versus 39.8% with placebo (Feuerstadt et al., 2022). The oral route eliminates the need for rectal administration, making it more convenient, though the cost is substantial, with a list price in the range of $17,500 per course.

Both products represent a shift from the previous model of using unprocessed donor stool under FDA enforcement discretion to manufactured, quality-controlled pharmaceutical products. This shift has significant implications for access, cost, and the future of FMT.

What happened to OpenBiome

OpenBiome was founded in 2013 as a nonprofit stool bank that screened donors, processed stool preparations, and shipped them to hospitals and clinics across the United States. For nearly a decade, it was the primary source of FMT material in the country, operating under FDA enforcement discretion, meaning the agency chose not to enforce the requirement for an Investigational New Drug (IND) application as long as certain conditions were met. At its peak, OpenBiome had supplied material for over 70,000 FMT treatments.

The approval of Rebyota and Vowst changed the regulatory calculus. The FDA signaled that enforcement discretion for conventional FMT would be narrowed as approved products became available. OpenBiome announced it would wind down its stool banking operations. By 2025, the transition was largely complete, and clinicians who had relied on OpenBiome for FMT material were directed to the commercial products or to the IND pathway for research use.

The closure was controversial. Advocates argued that OpenBiome provided affordable FMT access (often under $2,000 per treatment) while the commercial products were priced at $10,000 to $17,500. Critics noted that the enforcement discretion model had real safety gaps, including the 2019 incident in which two immunocompromised patients received FMT material from an OpenBiome preparation that contained ESBL-producing E. coli, resulting in one death (DeFilipp et al., 2019). That event accelerated safety reforms and donor screening requirements across the field.

Next-generation products: VE303 and defined consortia

The future of microbiome therapeutics may not involve donor stool at all. Several companies are developing defined consortia: products containing specific, characterized bacterial strains manufactured under pharmaceutical-grade conditions. The most advanced of these is VE303, developed by Vedanta Biosciences.

VE303 consists of 8 clonal, non-pathogenic Clostridia strains selected for their ability to restore colonization resistance against C. diff. A Phase 2 trial published in 2023 showed promising efficacy, with VE303-treated patients showing significantly higher rates of C. diff non-recurrence compared to placebo (Dsouza et al., 2023). Phase 3 trials are underway. If successful, VE303 would offer several advantages over donor-stool-derived products: standardized composition, no risk of donor-transmitted infections, and scalable manufacturing.

Other defined consortia in development include products from companies like Finch Therapeutics and Seres Therapeutics, though some programs have faced setbacks. The conceptual appeal is clear: if you can identify which specific bacteria are responsible for FMT's efficacy, you can manufacture them reliably without the variability, screening burden, and safety risks of using human donor material.

Expanding indications: IBD, IBS, metabolic conditions

While C. diff is the only approved indication, research into FMT for other conditions has been extensive, if not yet conclusive. The most studied alternative indication is ulcerative colitis (UC), where multiple randomized controlled trials have been conducted.

A landmark study by Paramsothy and colleagues randomized UC patients to receive multidonor FMT or placebo via colonoscopy and enema. The FMT group achieved clinical remission and endoscopic response at a significantly higher rate (27% versus 8%). While the absolute numbers are modest, they represented a statistically and clinically meaningful difference (Paramsothy et al., 2017). A similar trial by Costello and colleagues using anaerobically prepared donor stool showed even higher remission rates (32% versus 9%) (Costello et al., 2019). These are encouraging signals, but the effect sizes are smaller than for C. diff, the optimal protocol (number of infusions, donor selection, delivery route) is unclear, and large confirmatory trials are needed.

For IBS, the evidence is more mixed. A Norwegian trial by Johnsen and colleagues found improvement in IBS symptoms with FMT at 3 months, but the effect did not persist at 12 months (Johnsen et al., 2018). Other trials have shown no significant benefit over placebo. The 2024 AGA Clinical Practice Update explicitly stated that FMT should not be used for IBS outside of clinical trials.

Metabolic conditions, including obesity, type 2 diabetes, and metabolic syndrome, represent another area of active investigation. Small studies have shown that FMT from lean donors can temporarily improve insulin sensitivity in recipients with metabolic syndrome (Vrieze et al., 2012), but the effects have been modest and transient, and no study has demonstrated clinically meaningful weight loss or sustained metabolic improvement from FMT alone.

The 2024 AGA guidelines and what they recommend

The American Gastroenterological Association published updated guidance on FMT in 2024 that drew clear lines. For recurrent C. difficile infection (defined as 3 or more episodes), FMT is conditionally recommended after appropriate antibiotic therapy. The approved products (Rebyota and Vowst) are the preferred options, with conventional FMT via IND available in select centers.

For all other indications, the AGA did not recommend FMT outside of clinical trials. This includes ulcerative colitis, Crohn's disease, IBS, and metabolic conditions. The guideline cited insufficient evidence of efficacy, lack of standardized protocols, and unresolved safety questions as the primary reasons. This is not a statement that FMT definitely does not work for these conditions. It is a statement that the evidence is not yet strong enough to recommend it as a standard clinical intervention.

DIY FMT: understanding the real risks

The gap between the promise of FMT and the reality of limited access has driven some patients to attempt do-it-yourself fecal transplants at home. Online communities share protocols for selecting donors (often family members or partners), preparing stool, and self-administering via enema. The motivations are understandable: patients with treatment-resistant conditions who have exhausted conventional options and cannot afford or access approved products.

The risks are also real and serious. Professional FMT programs screen donors with extensive questionnaires, blood tests, and stool panels that test for C. diff, drug-resistant organisms, parasites, and viral infections including HIV, hepatitis B and C, and SARS-CoV-2. This screening process is not just bureaucratic overhead. It catches genuinely dangerous pathogens. The 2019 case that killed an immunocompromised patient involved ESBL-producing E. coli that passed through donor screening because ESBL testing was not yet routinely included (DeFilipp et al., 2019). That deficiency has since been corrected in professional programs, but DIY practitioners have no screening infrastructure at all.

What helps with understanding your options

The FMT landscape is changing rapidly, and staying informed about what is approved, what is investigational, and what is unproven matters for anyone considering this therapy. If you have recurrent C. diff, talk to your infectious disease specialist or gastroenterologist about Rebyota and Vowst. If you are interested in FMT for another condition, search clinicaltrials.gov for active studies in your area. Tracking your symptoms and treatment responses with tools like GLP1Gut can help you present a clear clinical picture to providers, which is especially important when discussing investigational options or seeking enrollment in a clinical trial.

The promise of microbiome-based therapeutics is real, but it is being realized incrementally through careful research, not through unregulated products or DIY procedures. The next few years will likely bring additional approved products for C. diff and possibly the first approvals for other conditions. In the meantime, evidence-based patience is the most responsible approach.